Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice

Abstract

Introduction Despite the growing evidence base for psychotropic drug treatment in pediatric patients, knowledge about the benefit-risk ratio in clinical practice remains limited. The ‘Therapeutic Drug Monitoring (TDM)-VIGIL’ study aimed to evaluate serious adverse drug reactions (ADRs) in children and adolescents treated with antidepressants and/or antipsychotics in approved (‘on-label’), and off-label use in clinical practice.

Methods Psychiatric pediatric patients aged 6-18 years treated with antidepressants and/or antipsychotics either on-label or off-label were prospectively followed between October 2014 and December 2018 within a multicenter trial. Follow-up included standardized assessments of response, serious ADRs and therapeutic drug monitoring.

Results 710 youth (age=14.6±2.2 years, female=66.6%) were observed for 5.5 months on average; 76.3% received antidepressants, 47.5% antipsychotics, and 25.2% both. Altogether, 55.2% of the treatment episodes with antidepressants and 80.7% with antipsychotics were off-label. Serious ADRs occurred in 8.3% (95%CI=6.4–10.6%) of patients, mainly being psychiatric adverse reactions (77.4%), predominantly suicidal ideation and behavior. The risk of serious ADRs was not significantly different between patients using psychotropics off-label and on-label (antidepressants: 8.1% vs. 11.3%, p=0.16; antipsychotics: 8.7% vs 7.5%, p=0.67). Serious ADRs occurred in 16.6% of patients who were suicidal at enrollment versus 5.6% of patients who were not suicidal (relative risk 3.0, 95%CI=1.9-4.9).

Conclusion Off-label use of antidepressants and antipsychotics in youth was not a risk factor for the occurrence of serious ADRs in a closely monitored clinical setting. Results from large naturalistic trials like ours can contribute to bridging the gap between knowledge from randomized controlled trials and real-world clinical settings.

Key words

antidepressants - antipsychotics - child - adverse drug reactions - safety

Publication History

Received: 09 September 2021
Received: 02 November 2021

Accepted: 29 November 2021

Article published online:
07 February 2022

• References

• 1 Piovani D, Clavenna A, Bonati M. Prescription prevalence of psychotropic drugs in children and adolescents: An analysis of international data. Eur J Clin Pharmacol 2019; 75: 1333-1346
• 2 Sultan RS, Correll CU, Schoenbaum M. et al. National patterns of commonly prescribed psychotropic medications to young People. J Child Adolesc Psychopharmacol 2018; 28: 158-165
• 3 Sharma AN, Arango C, Coghill D. et al. BAP position statement: Off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol 2016; 30: 416-421
• 4 Solmi M, Fornaro M, Ostinelli EG. et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta-review of 78 adverse effects. World Psychiatry 2020; 19: 214-232
• 5 Correll CU, Cortese S, Croatto G. et al. Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: An umbrella review. World Psychiatry 2021; 20: 244-275
• 6 Persico AM, Arango C, Buitelaar JK. et al. European Child and Adolescent Clinical Psychopharmacology Network. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur Neuropsychopharmacol 2015; 25: 1513-1531
• 7 Aagaard L, Hansen EH. Adverse drug reactions from psychotropic medicines in the paediatric population: Analysis of reports to the Danish Medicines Agency over a decade. BMC Res Notes 2010; 3: 176
• 8 Vitiello B, Correll C, van Zwieten-Boot B. et al. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009; 19: 629-635
• 9 Zimmerman KO, Smith PB, McMahon AW. et al. Duration of pediatric clinical trials submitted to the US Food and Drug Administration. JAMA Pediatr 2019; 173: 60-67
• 10 Aagaard L, Christensen A, Hansen EH. Information about adverse drug reactions reported in children: A qualitative review of empirical studies. Br J Clin Pharmacol 2010; 70: 481-491
• 11 Díaz-Caneja CM, Espliego A, Parellada M. et al. Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol 2014; 17: 1063-1082
• 12 Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am J Psychiatry 2002; 159: 469-473
• 13 Dörks M, Langner I, Dittmann U. et al. Antidepressant drug use and off-label-prescribing in children and adolescents in Germany: Results from a large population-based cohort study. Eur Child Adolesc Psychiatry 2013; 22: 511-518
• 14 Braüner JV, Johansen LM, Roesbjerg T. et al. Off-label-prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 2016; 36: 500-507
• 15 Schröder C, Dörks M, Kollhorst B et al. Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidemiol Drug Saf 2017; 26: 1395–1402
• 16 Schröder C, Dörks M, Kollhorst B. et al. Extend and Risk of Antipsychotic Off-Label-Use in Children and Adolescents in Germany between 2004 and 2011. J Child and Adolesc Psychopharmacol 2017; 27: 806-813
• 17 Zito JM, Derivan AT, Kratochvil CJ. et al. Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child and Adolescent Psychiatry and Mental Health 2008; 2: 24
• 18 Gerlach M, Greenhill L, Warnke A. Special features of psychopharmacological therapy in children and adolescents. Gerlach M, Warnke A, Greenhill L, eds. Psychiatric Drugs in Children and Adolescents. Basic Pharmacology and Practical Applications. Wien: Springer Verlag; 2014: 61-75
• 19 Rubio JM, Correll CU. Duration and relevance of untreated psychiatric disorders, 1: Psychotic disorders. J Clin Psychiatry 2017; (a) 78: 358-359
• 20 Rubio JM, Correll CU. Duration and relevance of untreated psychiatric disorders, 2: Nonpsychotic psychiatric disorders and substance use disorders. J Clin Psychiatry 2017; (b) 78: 464-465
• 21 Carnovale C, Brusadelli T, Zuccotti G. et al. The importance of monitoring adverse drug reactions in pediatric patients: The results of a national surveillance program in Italy. Expert Opin Drug Saf 2014; 13: 1-8
• 22 Gerlach M, Egberts K, Dang SY. et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf 2016; 15: 1477-1482
• 23 Minjon L, van den Ban E, de Jong E. et al. Reported adverse drug reactions in children and adolescents treated with antipsychotics. J Child Adolesc Psychopharmacol 2019; 29: 124-132
• 24 Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791
• 25 Galling B, Roldán A, Nielsen RE. et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: A systematic review and meta-analysis. JAMA Psychiatry 2016; 73: 247-259
• 26 De Hert M, Dobbelaere M, Sheridan EM. et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 2011; 26: 144-158
• 27 Pringsheim T, Panagiotopoulos C, Davidson J. et al. CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011; 20: 218-233
• 28 Fornaro M, Anastasia A, Valchera A et al. The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? Front. Psychiatry 2019; 10: 294
• 29 Dragioti E, Solmi M, Favaro A. et al. Association of antidepressant use with adverse health outcomes: A systematic umbrella review. JAMA Psychiatry 2019; 76: 1241-1255
• 30 Egberts K, Karwautz A, Plener PL. et al. Pharmacovigilance in child and adolescent psychiatry. Z Kinder Jugendpsychiatr Psychother 2015; 43: 21-28
• 31 Coates M, Spanos M, Parmar P. et al. A review of methods for monitoring adverse events in pediatric psychopharmacology clinical trials. Drug Saf 2018; 41: 465-471
• 32 Rodday AM, Parsons SK, Mankiw C. et al. Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics. J Child Adolesc Psychopharmacol 2015; 25: 351-361
• 33 Carleton BC, Smith MA, Gelin MN. et al. Paediatric adverse drug reaction reporting: Understanding and future directions. Can J Clin Pharmacol 2007; 14: e45-e57
• 34 Nguyen KA, Mimouni Y, Jaberi E. et al. Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. Therapie 2021; 76: 675-685
• 35 Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012; 68: 21-28
• 36 Palmaro A, Bissuel R, Renaud N. et al. Off-label prescribing in pediatric outpatients. Pediatrics 2015; 135: 49-58
• 37 Aagaard L, Hansen EH. Prescribing of medicines in the Danish paediatric population out with the licensed age group: characteristics of adverse drug reactions. Br J Clin Pharmacol 2011; 71: 751-757
• 38 Pratico AD, Longo L, Mansueto S. et al. Off-label use of drugs and adverse drug reactions in pediatric units: A prospective, multicenter study. Curr Drug Saf 2018; 13: 200-207
• 39 Neubert A, Dormann H, Weiss J. et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 1059-1067
• 40 Gore R, Chugh PK, Tripathi CD. et al. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol 2017; 12: 18-25
• 41 Bygdell M, Brunlöf G, Wallerstedt SM. et al. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol Drug Saf 2012; 21: 79-86
• 42 Egberts K, Plener P, Malzhan U. et al. Sicherheit von psychopharmaka bei kindern und jugendlichen in der klinischen praxis – Erkenntnisse einer prospektiven studie. Bulletin zur Arzneimittelsicherheit 2020; 3: 4-10
• 43 Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 2011; 44: 249-253
• 44 Remschmidt H, Schmidt M, Poustka F. eds. Multiaxiales Klassifikationsschema für psychische Störungen des Kinder- und Jugendalters nach ICD-10 der WHO. Bern: Huber Verlag; 2012
• 45 Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology – Revised. Rockville, MD: U.S. Department of Health, Education, and Welfare; Psychopharmacology Research Branch. Division of Extramural Research Programs. 1976: 218-222
• 46 Sass H, Wittchen H, Zaudig M. et al eds. Diagnostische kriterien des diagnostischen und statistischen manuals psychischer störungen. DSM-IV-TR. Hogrefe Verlag; Göttingen: 2003: 47-49
• 47 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
• 48 March J, Karayal O, Chrisman A. CAPTN: The pediatric adverse event rating scale. Novins DK, DeYoung, eds. The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Boston. 2007. 241.
• 49 Rafaniello C, Pozzi M, Pisano S. et al. Second generation antipsychotics in ‘Real-life’ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 2016; 15: 1-8
• 50 Cicala G, Barbieri MA, Santoro V et al. Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. Front. Psychiatry 2020; 11: 152
• 51 Schneeweiss S, Patrick AR, Solomon DH. et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010; 125: 876-888
• 52 Hilt RJ, Chaudhari M, Bell JF. et al. Side effects from use of one or more psychiatric medications in a population-based sample of children and adolescents. J Child Adolesc Psychopharmacol 2014; 24: 83-89
• 53 Rashed AN, Wong IC, Cranswick N. et al. Risk factors associated with adverse drug reactions in hospitalised children: International multicentre study. Eur J Clin Pharmacol 2012; 68: 801-810
• 54 Kurian J, Mathew J, Sowjanya K. et al. Adverse drug reactions in hospitalized pediatric patients: A prospective observational study. Indian J Pediatr 2016; 83: 414-419
• 55 Nor Aripin KN, Choonara I, Sammons HM. Systematic review of safety in paediatric drug trials published in 2007. Eur J Clin Pharmacol 2012; 68: 189-194
• 56 Kloosterboer SM, Vierhout D, Stojanova J. et al. Psychotropic drug concentrations and clinical outcomes in children and adolescents: A systematic review. Expert Opin Drug Saf 2020; 19: 873-890
• 57 Grau K, Fegert J, Plener PL. Psychopharmakologie in der KJP in Deutschland. Off-label-use und zulassung verfügbarer Fertigarzneimittel. Psychopharmakotherapie 2015; 22: 240-249
• 58 Trifirò G, Gini R, Barone-Adesi F. et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: Where does Italy stand?. Drug Saf 2019; 42: 347-363